Pharvaris reported positive phase III prevention data for hereditary angioedema attacks with deucrictibant, complementing earlier findings in acute treatment. Separately, surrogates of Wnt/VEGF biology also moved forward as Surrozen filed an IND in diabetic macular edema for SZN-8141, signaling continued interest in pathway-combination approaches for ocular angiogenesis and vascular leakage.